Compound: alfuzosin
SMILES: O=C(NCCCN(c1nc(N)c2cc(OC)c(cc2n1)OC)C)C3OCCC3
InChIKey: WNMJYKCGWZFFKR-UHFFFAOYSA-N
Synonyms: alfuzosin, 81403-80-7, Alfuzosina, Alfuzosine, Alfuzosinum, NSC-760065, N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide, 90347YTW5F, N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide, DTXSID6048549, CHEBI:51141, alphuzosine, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, alfusozine, N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)oxolane-2-carboxamide, N-(3-((4-imino-6,7-dimethoxy-3,4-dihydroquinazolin-2-yl)(methyl)amino)propyl)oxolane-2-carboximidic acid, N-{3-[(4-imino-6,7-dimethoxy-3,4-dihydroquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboximidic acid, RefChem:54078, DTXCID6028105, G04CA01, (+-)-N-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2-carboxamide, SL 77499, ALFLUZOCIN, ALFLUZOSIN, Alfuzosin (INN), N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide, MFCD00865792, CHEMBL709, 2-Furancarboxamide,N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, s5766, N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide, Alfuzosine [French], Alfuzosinum [Latin], Alfusosine, ALFUZOSIN [INN], Alfuzosina [Spanish], Alfuzosin [INN:BAN], n-(3-((4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)propyl)tetrahydrofuran-2-carboxamide, SMR000466340, Xatral (TN), HSDB 7290, SL 77-499, SL-7749910, Zatral, UNII-90347YTW5F, SR-01000759345, Mittoral;, Alfoten;, Urion;, ALFUZOSIN [MI], ALFUZOSIN [HSDB], 1100050-87-0, Prestwick0_000322, Prestwick1_000322, Prestwick2_000322, Prestwick3_000322, Spectrum2_000505, Spectrum3_001063, Spectrum4_001208, Spectrum5_000817, ALFUZOSIN [VANDF], GlyTouCan:G42137MR, ALFUZOSIN [WHO-DD], SCHEMBL34477, BSPBio_000323, BSPBio_002646, KBioGR_001616, MLS000759449, MLS001424027, MLS006011887, SPECTRUM1505263, Alfuzosin - Bio-X trade mark, SPBio_000429, SPBio_002244, BPBio1_000357, GTPL7109, orb1909164, SCHEMBL29355511, SCHEMBL29497289, KBio3_001866, HMS1922P11, HMS2051I10, HMS2093O06, HMS2235O22, HMS3369K03, HMS3393I10, HMS3749I05, HMS3886O22, HMS5085J05, Pharmakon1600-01505263, G42137MR, HY-B0192, BDBM50033110, CCG-39585, EBC-26907, MSK170269, NSC760065, STK643675, AKOS005574697, CCG-100859, DB00346, FA64935, NC00109, NSC 760065, SDCCGSBI-0206735.P002, NCGC00095152-01, NCGC00095152-02, NCGC00095152-03, NCGC00095152-04, NCGC00095152-05, NCGC00095152-07, NCGC00095152-19, 2-Furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-, BA164145, MS-26479, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl]tetrahydrofuran-2-carboxamide, SBI-0206735.P001, DB-056523, AB00514667, NS00000621, D07124, F84998, AB00514667-07, AB00514667-09, AB00514667-10, AB00514667_11, AB00514667_12, EN300-19766666, L001317, Q2736873, SR-01000759345-4, BRD-A09056319-001-02-2, BRD-A09056319-001-05-5, BRD-A09056319-003-03-6, BRD-A09056319-003-07-7, BRD-A09056319-003-08-5, (+/-)-N-(3-((4-AMINO-6,7-DIMETHOXYQUINAZOLIN-2-YL)(METHYL)AMINO)PROPYL)TETRAHYDROFURAN-2-CARBOXAMIDE, (+/-)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, 2-FURANCARBOXAMIDE, (+/-)-N-(3-((4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)METHYLAMINO)PROPYL)TETRAHYDRO-, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Theoretical properties:
molecular_formula: C19H27N5O4
molecular_weight: 389.4 g/mol
exact_mass: 389.20630436 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 8
heavy_atom_count: 28
topological_polar_surface_area: 112 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: In water, 92 mg/L at 25 °C /Estimated/
vapor_pressure: 4.56X10-13 mm Hg at 25 °C /Estimated/
Descriptions:
pubchem: Alfuzosin is a monocarboxylic acid amide, a member of quinazolines and a tetrahydrofuranol. It has a role as an antineoplastic agent, an antihypertensive agent and an alpha-adrenergic antagonist.
chembl: ALFUZOSIN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the α1 blocker class. It is used to treat benign prostatic hyperplasia (BPH).
As an antagonist of the α1-adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier.